Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00201123 · ClinicalTrials.gov registry record · Phase 2
Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT00201123 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 89 participants.
The verdict
NCT00201123, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
This study will evaluate the lung's immune response to mycobacterium tuberculosis (Mtb) infection and will modulate that response with interferon-gamma.
Interventions
- OTHER Placebo
- DRUG Aerosol Interferon-Gamma
- DRUG Subcutaneous interferon-gamma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2005-04 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00201123
The ClinicalTrials.gov registry entry for NCT00201123 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00201123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00201123 about?
NCT00201123 is a clinical study titled "Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs". This study will evaluate the lung's immune response to mycobacterium tuberculosis (Mtb) infection and will modulate that response with interferon-gamma.
What is the current status of trial NCT00201123?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2005-04. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00201123?
The interventions under investigation include: Placebo (OTHER), Aerosol Interferon-Gamma (DRUG), Subcutaneous interferon-gamma (DRUG).
Who is sponsoring clinical trial NCT00201123?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.